Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction

Jasper W. L. Hartog*, Ruud M. van de Wal, Casper G. Schalkwijk, Toshio Miyata, Wybren Jaarsma, H. W. Thijs Plokker, Leen M. van Wijk, Andries J. Smit, Dirk J. van Veldhuisen, Adriaan A. Voors

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Aims To investigate the relationship between advanced glycation end-products (AGEs) and diastolic function and the response to blood pressure treatment in patients with hypertension and diastolic dysfunction. Methods and results Data were analysed from 97 patients (aged 65 +/- 10 years, 36% male) who were randomly assigned to 6 months open-label treatment with either eprosartan on top of other anti-hypertensive drugs (n = 47) or other antihypertensive drugs alone (n = 50). Tissue AGE accumulation was measured using a validated skin-autofluorescence (skin-AF) reader (n = 26). Plasma N(epsilon)-(carboxymethyl) lysine (CML), N(epsilon)-(carboxyethyl) lysine (CEL), and pentosidine were measured by LC-MS/MS and HPLC. Diastolic function was assessed using echocardiography. Blood pressure was reduced from 157/91 to 145/84 mmHg (P median, E/A ratio (P = 0.84) and mean E' (P = 0.32) remained unchanged. Conclusion Although eprosartan did not decrease levels of AGEs, patients with lower skin-AF at baseline showed a larger improvement in diastolic function in response to either anti-hypertensive treatment compared with patients with higher skin-AF.
Original languageEnglish
Pages (from-to)397-403
JournalEuropean journal of heart failure
Issue number4
Publication statusPublished - Apr 2010


  • Hypertension
  • Advanced glycation end-products
  • Diastolic function
  • Skin-autofluorescence
  • Tissue velocity imaging

Cite this